NCT00647959

Fasting Study of Doxycycline Monohydrate Tablets 150 mg and Adoxa Tablets 150 mg

Single-Dose Fasting Bioequivalence Study of Doxycycline Monohydrate Tablets (150 mg; Mylan) and Adoxa Tablets (150 mg; Par) in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Mylan Pharmaceuticals Inc · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The objective of this study was to investigate the bioequivalence of Mylan's doxycycline monohydrate 150 mg tablets to Par's Adoxa® 150 mg tablets following a single, oral 150 mg (1 x 150 mg) dose administered under fasting conditions.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Doxycycline Tablets, 150mg	150mg, single dose fasting
DRUG	Adoxa Tablets 150 mg	150mg, single dose fasting

Timeline

• Start date: 2006-03-01
• Primary completion: 2006-03-01
• Completion: 2006-04-01
• First posted: 2008-04-01
• Last updated: 2024-04-24

Locations

1 site across 1 country: United States